BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 04, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Anti-vWF Nanobody: Extension study data

Data from 22 patients with stable angina undergoing percutaneous coronary intervention (PCI) in the open-label extension of a Phase Ib trial showed that IV ALX-0081 significantly inhibited vWF-mediated clotting as measured by complete inhibition of ristocetin cofactor vs. placebo (p<0.001), with...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >